MetaCap

CytomX Therapeutics (CTMX) vs DiaMedica Therapeutics (DMAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DiaMedica Therapeutics (DMAC) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 8.1% versus a loss of 47.7%. Over five years, DMAC leads with a +118.8% price change compared with -69.9% for CTMX. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $442.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%DMAC+8.13%
+80%+11%-58%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%DMAC+115.97%
+158%+26%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus DMAC key metrics
MetricCTMXDMAC
Share price$2.03$8.25
Market cap$442.55M$445.15M
1-day change-0.98%+2.87%
YTD return-52.35%+3.64%
1-year return-47.68%+8.13%
5-year return-69.93%+118.83%
EPS (TTM)$-0.51$-0.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$76.20M—
Revenue growth (YoY)-44.82%—
Net income (latest FY)$-17.37M$-32.77M
Operating margin-29.35%—
Net margin-22.79%—
52-week high$8.21$11.00
52-week low$1.87$5.25
Distance from 52-week high-75.27%-25.00%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+509.85%+96.97%
Average volume4.27M210.46K
Shares outstanding218.00M53.96M
Employees6935
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMAC has outperformed CTMX by 55.8 percentage points over the past year.

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

CTMX vs DMAC FAQ

Which is bigger, CytomX Therapeutics or DiaMedica Therapeutics?

DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $442.55M for CytomX Therapeutics (CTMX).

Which stock has performed better over the past year, CTMX or DMAC?

DMAC returned +8.13% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are CytomX Therapeutics and DiaMedica Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons